Integra LifeSciences (NASDAQ:IART) Announces Quarterly Earnings Results

Integra LifeSciences (NASDAQ:IART - Get Free Report) posted its earnings results on Monday. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.02), Zacks reports. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $382.65 million for the quarter, compared to analysts' expectations of $381.17 million. During the same period in the previous year, the company earned $0.55 earnings per share. The company's revenue was up 3.7% compared to the same quarter last year. Integra LifeSciences updated its Q2 2025 guidance to 0.400-0.450 EPS and its FY 2025 guidance to 2.190-2.290 EPS.

Integra LifeSciences Stock Performance

NASDAQ IART traded down $0.02 during trading hours on Wednesday, hitting $12.73. 1,486,262 shares of the stock were exchanged, compared to its average volume of 1,042,489. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. Integra LifeSciences has a 12-month low of $11.60 and a 12-month high of $32.66. The company has a market cap of $983.39 million, a price-to-earnings ratio of -141.43, a price-to-earnings-growth ratio of 0.73 and a beta of 1.27. The stock has a 50-day moving average of $19.31 and a 200 day moving average of $21.96.

Wall Street Analyst Weigh In

A number of equities analysts have commented on IART shares. Argus raised Integra LifeSciences from a "hold" rating to a "buy" rating in a report on Monday, March 31st. Truist Financial reduced their price target on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. JPMorgan Chase & Co. reduced their price objective on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a report on Tuesday. Finally, Wells Fargo & Company dropped their target price on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a report on Tuesday. Four research analysts have rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat, Integra LifeSciences has an average rating of "Hold" and a consensus target price of $19.88.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.